Study of Transcranial Direct Current Stimulation to Treat Epilepsy
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT05673915
- Status
- Recruiting
Conditions
- Focal Epilepsy
- Generalized Onset Epilepsy
- Sleep-related Epileptic Encephalopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) — DEVICEStimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
- ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS) — DEVICEStimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
Study Details
The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
Key Dates
- Start date
- Apr 12, 2023
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: tDCS Treatment A (Low Amplitude)Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.
- Experimental: tDCS Treatment B (High Amplitude)Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.
Primary Outcome Measure
Seizure Count [ Time Frame: 2 months ]
Central Contacts
- Precylla Ruiz507-538-6606
- Izzie Meunier507-538-6337
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 | - |
Find similar trials in Rochester, MN
By research site
Related Studies
- An Open-label Study of XEN1101 in EpilepsyPHASE3 · Enrolling By Invitation · Xenon Pharmaceuticals Inc. · Phoenix, Arizona
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPHASE2/PHASE3 · Recruiting · Biohaven Therapeutics Ltd. · Phoenix, Arizona
- Long-term Safety and Tolerability of BHV-7000PHASE2 · Enrolling By Invitation · Biohaven Therapeutics Ltd. · Birmingham, Alabama
- Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and WearablesRecruiting · Mayo Clinic · Rochester, Minnesota